Efficacy and safety of dimethyl fumarate in the treatment of multiple sclerosis：a meta-analysis

LI Fengyun; LAN Rui; ZHAO Duo; LIU Fugui; CHEN Liangchen

doi:10.6039/j.issn.1001-0408.2024.14.18

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of dimethyl fumarate in the treatment of multiple sclerosis：a meta-analysis

更新时间：2024-07-25

- Efficacy and safety of dimethyl fumarate in the treatment of multiple sclerosis：a meta-analysis
- ZHONGGUO YAOFANG Vol. 35, Issue 14, Pages: 1776-1780(2024)
- 作者机构：
  
  1.河南中医药大学第一附属医院脑病科，郑州　450000
  2.河南中医药大学第一临床医学院，郑州　450000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.14.18
  CLC： R969
- Published：30 July 2024，
  
  Received：28 February 2024，
  
  Revised：22 June 2024，
- 稿件说明：
扫描看全文
李凤云,兰瑞,赵铎等.富马酸二甲酯治疗多发性硬化疗效与安全性的Meta分析 ^Δ[J].中国药房,2024,35(14):1776-1780.

LI Fengyun,LAN Rui,ZHAO Duo,et al.Efficacy and safety of dimethyl fumarate in the treatment of multiple sclerosis：a meta-analysis[J].ZHONGGUO YAOFANG,2024,35(14):1776-1780.
李凤云,兰瑞,赵铎等.富马酸二甲酯治疗多发性硬化疗效与安全性的Meta分析 ^Δ[J].中国药房,2024,35(14):1776-1780. DOI： 10.6039/j.issn.1001-0408.2024.14.18.

LI Fengyun,LAN Rui,ZHAO Duo,et al.Efficacy and safety of dimethyl fumarate in the treatment of multiple sclerosis：a meta-analysis[J].ZHONGGUO YAOFANG,2024,35(14):1776-1780. DOI： 10.6039/j.issn.1001-0408.2024.14.18.

摘要

目的

评价富马酸二甲酯（DMF）治疗多发性硬化（MS）的疗效和安全性。

方法

检索中国生物医学文献服务系统、Web of Science、PubMed、the Cochrane Library、Embase、中国知网、万方数据、维普网，收集DMF（试验组）对比其他药物或安慰剂（对照组）的随机对照试验。筛选、提取数据，评价文献质量后，采用RevMan 5.3软件进行Meta分析。

结果

共纳入6篇文献，共计638例患者。Meta分析结果显示，试验组治疗后病灶发生变化的患者比例显著低于对照组[MD＝－0.65，95%CI（－1.27，－0.02），

＝0.04

]

；两组患者的复发率[RR＝1.06，95%CI（0.52，2.17），

＝0.88

]

、治疗后出现新发病灶患者比例[RR＝1.05，95%CI（0.62，1.80），

＝0.85

]

、治疗后临床扩展致残量表评分[MD＝0.02，95%CI（－0.18，0.23），

＝0.82

]

、不良事件发生率[RR＝1.33，95%CI（0.97，

1.84），

＝0.08

]

、严重不良事件发生率[RR＝0.95，95%CI（0.48，1.90），

＝0.89

]

比较，差异均无统计学意义。敏感性分析结果显示，本研究所得复发率和不良事件发生率结果不稳健，其他结果稳健。

结论

DMF可在一定程度上控制MS患者的病灶进展，未增加不良事件及严重不良事件的发生风险，但在降低复发率、控制残疾进展方面未有显著优势。

Abstract

OBJECTIVE

To evaluate the efficacy and safety of dimethyl fumarate （DMF） in the treatment of multiple sclerosis （MS）.

METHODS

Retrieved from CBM， Web of Science， PubMed， the Cochrane Library， Embase， CNKI， Wanfang Data， and VIP， randomized controlled trials （RCTs） about DMF （trial group） versus other drugs or placebo （control group） were collected. After data screening and extraction， quality evaluation， meta-analysis was conducted by using RevMan 5.3 software.

RESULTS

A total of 6 literature were included， involving 638 patients. Results of meta-analysis showed that the proportion of patients with lesion changes after treatment in the trial group was lower than control group [MD＝－0.65， 95%CI（－1.27，－0.02），

＝0.04

]

； there was no statistical significance in recurrence rate [RR＝1.06， 95%CI（0.52，2.17），

＝0.88

]

， the proportion of patients with new lesions after treatment [RR＝1.05， 95%CI（0.62，1.80），

＝0.85

]

， expanded disability status scale after treatment [MD＝0.02，95%CI （－0.18， 0.23），

＝0.82

]

， the incidence of adverse events [RR＝1.33， 95%CI（0.97， 1.84），

＝0.08

]

or severe adverse events [RR＝0.95，95%CI（0.48，1.90），

＝0.89

]

between 2 groups. Results of sensitivity analysis showed the study obtained unstable recurrence rate and the incidence of adverse events， while other results were robust.

CONCLUSIONS

DMF can control the lesion progression in MS patients to some extent and doesn’t increase the incidence of adverse events and serious adverse events， but there is no significant advantage in reducing the recurrence rate and controlling the disability progression.

关键词

富马酸二甲酯多发性硬化疾病修饰治疗复发率不良事件

Keywords

multiple sclerosisdisease modification treatmentrecurrence rateadverse event

references

中国免疫学会神经免疫分会，中华医学会神经病学分会神经免疫学组.多发性硬化诊断和治疗中国专家共识：2018版[J]. 中国神经免疫学和神经病学杂志，2018，25（6）：387-394.

Neuroimmunology Division of Chinese Society for Immunology，Neuroimmunology Group of Neurology Division of Chinese Medical Association. Chinese consensus on diagnosis and treatment on multiple slcerosis：2018 version[J]. Chin J Neuroimmunol Neurol，2018，25（6）：387-394.

CALLEGARI I，DERFUSS T，GALLI E. Update on treatment in multiple sclerosis[J]. Presse Med，2021，50（2）：104068.

钟晓南，胡学强. 《多发性硬化诊断和治疗中国专家共识（2018版）》解读[J]. 中国神经免疫学和神经病学杂志，2019，26（2）：80-83.

ZHONG X N，HU X Q. Interpretation of Chinese expert Consensus on Diagnosis and Treatment of Multiple Sclerosis：2018 Edition[J]. Chin J Neuroimmunol Neurol，2019，26（2）：80-83.

韦石凤，赵志刚. 多发性硬化症的药物治疗及药学监护[J]. 医药导报，2023，42（5）：742-749.

WEI S F，ZHAO Z G. Drug treatment and pharmaceutical care of multiple sclerosis[J]. Her Med，2023，42（5）：742-749.

YAMOUT B，SAHRAIAN M，BOHLEGA S，et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis：2019 revisions to the MENACTRIMS guidelines[J]. Mult Scler Relat Disord，2020，37：101459.

王柳清，朱峰，薛群，等. 多发性硬化疾病修饰治疗药物的临床应用现状[J]. 临床药物治疗杂志，2023，21（10）：6-11.

WANG L Q，ZHU F，XUE Q，et al. Clinical application status of disease-modifying therapy drug for multiple sclerosis[J]. Clin Med J，2023，21（10）：6-11.

谭红梅，全超. 多发性硬化治疗共识组：关于多发性硬化疾病修饰治疗的立场声明（白皮书）的解读[J]. 中国临床神经科学，2023，31（5）：547-549，557.

TAN H M，QUAN C. Interpretation of multiple sclerosis therapy consensus group：position statement on disease-modifying therapies for multiple sclerosis：white paper[J]. Chin J Clin Neurosci，2023，31（5）：547-549，557.

陈涓涓，邱伟. 多发性硬化疾病修饰治疗药物转换的证据与策略[J]. 中国神经免疫学和神经病学杂志，2020，27（3）：222-226，230.

CHEN J J，QIU W. Evidence and strategies for disease-modifying therapy switches in multiple sclerosis[J]. Chin J Neuroimmunol Neurol，2020，27（3）：222-226，230.

芮明军，杜夕雯，谢丽，等. 富马酸二甲酯治疗复发缓解型多发性硬化的成本效果分析[J]. 世界临床药物，2022，43（11）：1475-1485.

RUI M J，DU X W，XIE L，et al. Cost-utility analysis of dimethyl fumarate compared with terifunomide for the treatment of relapsing multiple sclerosis in China[J]. World Clin Drug，2022，43（11）：1475-1485.

李伟，孙轶竹，方佳，等. 富马酸二甲酯治疗复发型多发性硬化的最小成本分析[J]. 中国药房，2022，33（24）：3005-3009.

LI W，SUN Y Z，FANG J，et al. Cost-minimization analysis of dimethyl fumarate in the treatment of relapsing multiple sclerosis[J]. China Pharm，2022，33（24）：3005-3009.

HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials[J]. BMJ，2011，343：d5928.

OCHI H，NIINO M，ONIZUKA Y，et al. 72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis：analysis of the randomised，double blind，placebo-controlled，phase Ⅲ APEX study and its open-label extension[J]. Adv Ther，2018，35（10）：1598-1611.

MASJEDI S S，ETEMADIFAR M，ZADEH N M，et al. Assessment of fingolimod versus dimethyl fumarate for the treatment of multiple sclerosis；a 24-month follow-up study[J]. Am J Clin Exp Immunol，2021，10（3）：86-92.

HØJSGAARD CHOW H，TALBOT J，LUNDELL H，et al. Dimethyl fumarate treatment in patients with primary progressive multiple sclerosis：a randomized，controlled trial[J]. Neurol Neuroimmunol Neuroinflamm，2021，8（5）：e1037.

VERMERSCH P，SCARAMOZZA M，LEVIN S，et al. Effect of dimethyl fumarate vs interferon β-1a in patients with pediatric-onset multiple sclerosis：the CONNECT randomized clinical trial[J]. JAMA Netw Open，2022，5（9）：e2230439.

SVENNINGSSON A，FRISELL T，BURMAN J，et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden：a rater-blinded，phase 3，randomised controlled trial[J]. Lancet Neurol，2022，21（8）：693-703.

MACMANUS D G，MILLER D H，KAPPOS L，et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis[J]. J Neurol，2011，258（3）：449-456.

BLAIR H A. Dimethyl fumarate：a review in relapsing-remitting MS[J]. Drugs，2019，79（18）：1965-1976.

中华医学会神经病学分会神经免疫学组. 多发性硬化诊断与治疗中国指南：2023版[J]. 中华神经科杂志，2024，57（1）：10-23.

Neuroimmunology Group of Neurology Society of Chinese Medical Association.Chinese guidelines for diagnosis and treatment of multiple sclerosis：2023 edition[J]. Chin J Neurol，2024，57（1）：10-23.

乔本玉. 51例苏州地区多发性硬化患者的临床特征及预后影响因素分析[D]. 苏州：苏州大学，2022.

QIAO B Y. Analysis of clinical characteristics and prognostic factors of 51 patients with multiple sclerosis in Suzhou area[D].Suzhou：Soochow University，2022.

MAJKUTEWICZ I. Dimethyl fumarate：a review of preclinical efficacy in models of neurodegenerative diseases[J]. Eur J Pharmacol，2022，926：175025.

HOSSEINI A，MASJEDI A，BARADARAN B，et al. Dimethyl fumarate：regulatory effects on the immune system in the treatment of multiple sclerosis[J]. J Cell Physiol，2019，234（7）：9943-9955.

VOLLMER B L，NAIR K，SILLAU S，et al. Rituximab versus natalizumab，fingolimod，and dimethyl fumarate in multiple sclerosis treatment[J]. Ann Clin Transl Neurol，2020，7（9）：1466-1476.

PROSPERINI L，HAGGIAG S，RUGGIERI S，et al. Dimethyl fumarate or teriflunomide for relapsing-remitting multiple sclerosis：a meta-analysis of post-marketing stu-dies[J]. Neurotherapeutics，2023，20（5）：1275-1283.

LIANG G，CHAI J L，NG H S，et al. Safety of dimethyl fumarate for multiple sclerosis：a systematic review and meta-analysis[J]. Mult Scler Relat Disord，2020，46：102566.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Signal mining and evaluation of adverse events of four biological agents for the treatment of inflammatory bowel disease

Signal mining and analysis of adverse events of oseltamivir， zanamivir and baloxavir marboxil

Safety comparison of high-dose methotrexate via different intravenous infusion devices in pediatric patients with malignant brain tumors

Excavation and evaluation of adverse reaction signals of 4 kinds of imported PD- 1/PD-L1 inhibitors

Data-mining of Adverse Drug Events Signals for Tocilizumab Based on US FAERS Database

Related Author

DU Qingqing

QIAN Yan

LIU Rui

LIU Defeng

LIU Yao

LI Yanping

SU Hui

ZHANG Ni

Related Institution

Dept. of Pharmacy， the Second Affiliated Hospital of Chongqing Medical University

Department of Pharmacy， Daping Hospital， Army Medical University

Dept. of Pharmacy/Beijing Key Lab for Biometric Evaluation of Clinical Rational Drug Use，Beijing Shijitan Hospital Affiliated to Capital Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰